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Abstract
Background: Cannabis use can frequently have adverse affects in those that use it and these can be amplified by
various characteristics of an individual, from demographic and environmental variations to familial predisposition for
mental illnesses.
Methods: The current study of 100 individuals, who were cannabis users during their adolescence and may still be
users, was a survey of the self perceived effects of cannabis and their correlates. A reliable family member was also
interviewed for determination of family history of various major mental illnesses and substance use.
Results: As many as 40% of cannabis users had paranoid feelings (suspiciousness) when using cannabis, although
the most frequent effect was feeling relaxed (46%). Having a familial background for mental illnesses such as
depression or schizophrenia did not determine the effects of cannabis nor its pattern of use, although the number
of subjects with such a history was small. An age at which an individual began using cannabis did have an effect
on how heavily it was used and the heavier the cannabis use, the more likely the individual was also to have had
psychotic symptoms after use. There were no sex differences in effects of cannabis. These results are tempered by
the reliance on self-report for many of the variables ascertained.
Conclusion: Cannabis can frequently have negative effects in its users, which can be amplified by certain
demographic and/or psychosocial factors. Thus, users with a specific profile may be at a higher risk of unpleasant
effects from cannabis use and caution should be noted when cannabis is administered to young people for
medicinal purposes.
Background
Cannabis use is wide-spread among adolescents and young
adults in the USA and world-wide [1]. There has also been
considerable debate about whether it is truly a dangerous
recreational drug or is relatively harmless and should be
legalized [2]. The outcome of this debate depends largely
on whether cannabis can be shown to cause deleterious
changes in the brain and cognition. While some changes in
memory have been noted in habitual cannabis users, [3,4]
they may recover after cessation of drug use [5] and there
has never been consistently replicated evidence of clear
structural or structural brain changes in heavy users [6].
Quantitative analysis on cannabis users and its effects
presents researchers with several challenges. First, it is
difficult to quantify the precise amounts of the drug that
are taken by each user over time given that the quantity
varies considerably depending on the quality of pur-
chased drug, and the terminology used. The majority of
cannabis users describe their use in terms of “joints”,
“bowls” or “blunts” which can all vary in volume [7,8].
Moreover, those individuals who have used cannabis
heavily have likely tried and been frequent users of other
drugs as well. At a minimum they seem to be frequent
alcohol users. Thus it is difficult to tease apart the effects
of cannabis from other substances.
Why young people have the need to use cannabis
on a frequent basis is an interesting question and
may be associated with their underlying personality
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adolescence, as well as any psychiatric disturbances
they have experienced, such as depression, anxiety or
even psychotic symptoms [1]. Family history of these
disorders may also influence characteristics of canna-
bis use, as symptoms in genetically vulnerable popula-
tions could be initiated by heavy substance use.
When people use cannabis, it may acutely produce a
wide variety of effects, from a feeling of euphoria and
well being, to one of anxiety and irritability. Why the
effects vary so much between individuals is unknown,
but is likely to be associated with genetic, environmental,
age, gender and other psychological factors as listed




One hundred individuals from the New York City com-
munity participated in this study. They were recruited
by advertizing in the electronic classified program,
“Craig’s List” requesting research volunteers between the
ages of 18–35 who frequently use or used cannabis ini-
tially during their adolescent years. Potential study parti-
cipants were telephone screened and eliminated if found
to meet the following exclusion criteria: previous
hospitalization for a psychiatric illness, admitted to using
other recreational drugs other than cannabis more than
5 times in a lifetime, did not have a close family inform-
ant available for obtaining family history information.
Cannabis use during adolescence was required because
this period of life is postulated to be a time in brain de-
velopment that could be more vulnerable to the effects
of cannabis than later in adulthood.
Measures
All 100 study participants were interviewed using the
Diagnostic Interview for Genetic Studies [9] supplemen-
ted by questions taken from the Psychiatric Research
Interview for Substance and Mental Disorders [10] and
combined with the Structured Interview for Schizotypy
[11]. A family pedigree was drawn with information
obtained from the participant, and when available, at
least one family informant was interviewed regarding ill-
nesses known to occur within the family using the Fam-
ily Interview for Genetic Studies [12], a structured
interview aimed at obtaining information about family
members from a reliable and knowledgeable family in-
formant. All individuals and their family members par-
ticipating in this study received code numbers and no
identifying information was obtained about other ill
members in the family. This protocol was approved by
the Institutional Review Boards of: The New York
University Langone School of Medicine; St. Luke’s
Roosevelt Hospital Center, New York City; The Nathan
Kline Institute, Orangeburg, NY; and the VA Boston
Healthcare System where Dr. DeLisi was employed.
The effects felt by each participant while administering
cannabis were solicited by a structured oral question-
naire aimed at yes/no answers about a variety of specific
experiences (see Table 1).
All coded data extracted from interviews including
demographic information, psychiatric symptoms, diag-
noses, alcohol use, amount of cannabis use, age of onset,
and acute effects of cannabis were entered into an Excel
database by one researcher and data rechecked for ac-
curacy. DSM-IV diagnoses (Axis I for major psychiatric
illness and Axis II for personality disorders) were made
on all participants by a research psychiatrist using all
available information collected during the interview.
Statistical analysis
All statistical analyses were performed using SPSS, ver-
sion 18. Univariate analyses were used to examine the
frequency distribution across individual variables and are
presented in the paper as the descriptive analysis. For
univariate analyses of continuous variables, means and
standard deviations were calculated. A number of bivari-
ate analyses (simultaneous analysis of two variables)
were performed to see if one variable is related to an-
other variable. For comparison of nominal (categorical)
bivariate data, the chi-square statistic was used (i.e. Race
by Gender). For comparison of interval (continuous) bi-
variate data the independent t-test statistic was used (i.e.
age at onset in males vs. females). Other associations
and causal relationships were looked at by calculating
correlation coefficients. The Pearson’s correlation was
used to find a correlation between at least two continu-
ous variables. In the case of analyzing the correlation be-
tween two binary variables (i.e. yes-no, absent-present)
we used the Phi-statistic. The phi coefficient is a meas-
ure of the degree of association between two binary vari-
ables and is similar to the correlation coefficient in its
interpretation. Since we examined a number of pair-wise
comparisons, a conservative Bonferroni adjustment was
used to manage multiple significant levels (p-values).
For estimating the intensity (quantity-frequency) of
cannabis use, a Likert scale was created to assign num-
bers from 1 to 5 based on the frequency of cannabis
use by the subjects. The scale consisted of ranging from
5=very frequent, 4=frequent, 3=occasionally, 2=rarely,
and 1=very rarely. For example, heavy Cannabis users
who used multiple times a day were assigned a 5 and
subjects that used cannabis 1–2 times a month were
assigned a 2. Next, independent t-tests were used to
compare the frequency of usage with the cannabis self
reported symptoms. Pearson correlations were used to
correlate cannabis frequency with other quantitative
Camera et al. Harm Reduction Journal 2012, 9:15 Page 2 of 7
http://www.harmreductionjournal.com/content/9/1/15variables such as age of onset of Cannabis use and dur-
ation of use.
A factor analysis was applied to the data set in order
to determine whether the list of 16 cannabis induced ef-
fect symptoms might be attributed largely or entirely by
a much smaller number of variables. Factor analysis is
often used to identify a small number of factors that ex-
plain most of the variance observed in a much larger
number of manifest variables. The assumption here is
that underneath our indicators there are continuous la-
tent variables which allow for factor analysis and the
corresponding correlation matrix. We used Principal
Component Analysis as the extraction method employ-
ing Varimax Rotation. Components extracted consisted
of variables with a factor loading score of .40 or greater.
Each factor was validated by examining the correspond-
ing Pearson and Phi correlation matrix to determine that
the defining variables were highly correlated. Once the
factors have been determined SPSS creates one new vari-
able for each factor in the final solution. These new fac-
tor variables can in-turn by used in further analyses of
association with other original variables.
Results
Table 2 lists all demographic characteristics of the co-
hort. The study included 48 males (mean age +/−SD:
22.54 +/− 2.60) and 52 females (21.83+/−2.63). 75% of
the individuals had no psychiatric diagnoses, while 19%
were diagnosed with major depression, 9% satisfied cri-
teria for schizotypal personality disorder, 4% for para-
noid personality disorder, and 9% for other personality
disorders or traits partially satisfying criteria for a
spectrum of personality disorders. 26% individuals
scored positively on the SIS for social anxiety.
The variety of self-reported effects of cannabis was
reduced to 16 major types and the proportion of sub-
jects having them listed in Table 1. The most com-
mon effect was to feel relaxed, calm and clear
minded (46%), while as many as 40% experienced sus-
piciousness (labeled as feeling “paranoid” and other
delusions). 39% of the controls reported to have an
altered appetite and 25% admitted to altered concen-
tration and some memory loss.
Factor analyses of all cannabis effects in Table 1 using a
Rotated Component Matrix resulted in 5 main components
listed in Table 3: Factor 1(increased irritability/intensity);
Factor 2 (relaxed); Factor 3 (Hallucinations/delusions); Fac-
tor 4: (Hallucinations and other perceptual disturbances);
Factor 5: (depression).
In order to determine variables that might be asso-
ciated with main components of the effects of cannabis,
both T tests and Pearson’s correlations were performed
reflected in Table 4. Both factors 2 and 4 were associated
with having had at least 1 episode of major depression
(T=4.3, p <0.0000 and T=2.36, p=0.02). Referring to
Table 5, having a family history of schizophrenia in a
first or second degree relative was associated with factor
1 (T=2.15, p=.04). Factor 3 was associated with age of
onset of cannabis use (Pearson’sr = −0.29, p <0.004) so
that the earlier the onset of use the greater the likelihood
of feeling paranoid (suspiciousness) and having other
delusions with use. The age of onset of alcohol use was
Table 1 Self reported effects of cannabis acutely
Controls N=100
Variable # Variable description Reported yes (%)
1 Paranoia, Delusions 40
2 Hallucinations 7
3 Relaxed, Calm, Clear Minded 46
4 Altered Appetite 39
5 Altered Sleeping Patterns, Tired, Sleepy 17
6 Disturbed, Bad Highs, Disruption of Daily Activities 7
7 Sad, Lonely, Depressed, Lack of Motivation, Lazy 12
8 Altered Concentration, Loss of Memory 25
9 Anxious, Irritable, Panic Attacks 11
10 Altered Sex Drive 11
11 Heightened Senses, Perception, Intense Feelings, Mood Swings, Alertness 11
12 Fun, Happy, Euphoric, Better, More Enjoyable 20
13 Headache, Light Headed, Feint, high Blood Pressure 10
14 Racing Thoughts, Fixated Thoughts 7
15 Introspective, Insightful, Creative 7
16 Loss of Reality, Feeling Weird, Body Sensations, Out of It 15
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use (r=.28, p <0.01).
Chi-square analyses revealed that those cannabis
users who also used alcohol were significantly more
likely to report having hallucinations with cannabis use
(chi-square=10.5, p <0.001). In Table 6, those cannabis
users who experienced at least one episode of depres-
sion were significantly more likely to feel relaxed, calm
and clear minded with cannabis use (chi-square=5.9, p
<0.01), as well as having reported an altered appetite
(chi-square=11.2, p <0.001). Having a family history of
bipolar disorder was significantly related to feeling
depressed, sad, lonely with lack of motivation with
cannabis use (chi-square=8.7, p <0.003). Having a
family history of alcohol abuse was significantly
related to having racing and fixated thoughts with
cannabis use (chi-square =10.0, p <0.002). Family his-
tory of alcoholism was not associated with alcohol usage
of the cannabis users (chi-square=2.5, p <0.112). Also
family history of Bipolar Disorder was not associated
with reporting feeling sad, lonely, or depressed while
using cannabis (chi-square=8.7, p <0.003), (See Table 7).
All other analyses were non significant, except having
a family history of bipolar disorder which was associated
with depressive symptoms (chi-square=5.206, p=0.023).
Having a family history of schizophrenia was not
associated with having delusions or hallucinations
(chi-square=0.154; p=0.695), although the N for
t h o s ew i t haf a m i l yh i s t o r yw a ss m a l la n dm a yb e
underpowered (10/100), as a 95% CI around the
observed odds ratio ranges between 0.17 and 14.44.
Having a past history of major depression was not
Table 2 Demographic variables of the cohort
Controls N=100 Males N=48 Females N=52
Demographics
Age
Mean (SD) 22.17 (2.63) 22.54 (2.60) 21.83 (2.63)
Age Depression Diagnosis
Mean (SD) 17.54 (3.64) 17.43 (4.2) 17.67 (3.27)
Age Onset of Alcohol Usage
Mean (SD) 15.91 (2.38) 15.73 (2.54) 16.09 (2.23)
Race/Ethnicity (%)
Caucasian 40 (40%) 25 (52%) 15 (29%)
African American, Black 27 (27%) 13 (27%) 14 (27%)
Hispanic, Latino 24 (24%) 7 (15%) 17 (33%)
Asian 4 (4%) 1 (2%) 3 (6%)
Mixed 5 (5%) 2 (4%) 3 (6%)
Psychiatric Lifetime Diagnoses
No Diagnosis 75% 35 (73%) 40 (77%)
Depression 19% 9 (19%) 10 (19%)
Schizotypal Traits 9% 3 (6%) 6 (12%)
Paranoid Personality 4% 2 (4%) 2 (4%)
Antisocial Personality 5% 5 (10%) 0
Social Anxiety 26% 12 (25%) 14 (27%)
ADHD 2% 2 (4%) 0
Dysthymia 2% 1 (2%) 1(2%)
Alcohol Use 91% 45(94%) 46 ( 89%
Family History
Schizophrenia 10% 3(6%) 7 (14%)
Manic Depression 14% 8 (17%) 6 (12%)
Depression 33% 15 (31%) 18 (35%)
Alcohol Abuse 32% 15 (31%) 17(33%)
Drug Abuse 35% 16(33%) 19 (37%)
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(factor 5). Males and females did not appear to have
any different effects of cannabis.
Discussion
Cannabis use produces variable effects in different users.
Because cannabis can be considered a major public
health problem when used frequently, and yet has now
been legalized in some places for medicinal purposes, it
would be important to know what characteristics of
individuals make them more vulnerable to adverse sub-
jective effects of cannabis, the so-called “bad trips.”
Family history of psychiatric illnesses was ascertained
from family member interviews in order to determine if
a genetic predisposition could determine the types of
effects one gets when using cannabis. Since major de-
pression is a biologically-based disorder with a genetic
predisposition, any correlations with a history of depres-
sion may make one more biologically vulnerable to be-
coming depressed when using cannabis. However,
having been prone to major depression did not appear
to be associated with becoming depressed with cannabis
use, while having a family history of bipolar disorder did.
Interestingly, a history of past major depression was
associated with not only the “relaxed” factor, but also with
hallucinations and perceptual alternations. Although
having a family history of schizophrenia was associated
with increased irritability and intensity, it was not asso-
ciated with hallucinations or having paranoia and other
delusions. While interesting, our failure to find this associ-
ation may be due to the limited power of this study (having
only 10 probands with a family history of schizophrenia).
Sex or ethnicity of the individual did not appear to deter-
mine what types of effects of cannabis were reported. An





1 Paranoia, Delusions 0.58
2 Hallucinations 0.43 0.49
3 Relaxed, Calm, Clear Minded 0.80
4 Altered Appetite 0.75
5 Altered Sleeping Patterns, Tired, Sleepy 0.75
6 Disturbed, Bad Highs, Disruption of Daily Activities 0.71
7 Sad, Lonely, Depressed, Lack of Motivation, Lazy 0.80
8 Altered Concentration, Loss of Memory
9 Anxious, Irritable, Panic Attacks 0.55
10 Altered Sex Drive
11 Heightened Senses, Perception, Intense Feelings, Mood Swings, Alertness 0.72
12 Fun, Happy, Euphoric, Better, More Enjoyable 0.50
13 Headache, Light Headed, Faint, High B.P. 0.81
14 Racing Thoughts, Fixated Thoughts
15 Introspective, Insightful, Creative 0.70
16 Loss of Reality, Feeling Weird, Body Sensations, Out of It 0.72
Extraction Method: Principal Component Analysis
Rotation Method: Varimax with Kaiser Normalization
a. Rotation converged in 13 iterations
Note that 5 main components emerge: Factor 1(increased irritability/intensity); Factor 2 (relaxed); Factor 3 (Hallucinations/delusions); Factor 4 (Hallucinations and
other perceptual disturbances); Factor 5 (depression).
Table 4 Significant correlations of cannabis use
Correlation
Variables Coefficient P value
Age & Duration of MJ usage 0.582 0.000
Age & Age Diagnosis Depression 0.581 0.037
Age of Onset MJ Use & Duration of MJ Use −0.517 0.000
Age of onset Alcohol Use & Age of onset MJ Use 0.450 0.000
Age of onset MJ use & Factor Component
3 (Paranoia/Delusions & Hallucinations)
−0.255 0.010
MJ Frequency of use &Years of MJ Use 0.318 0.001
MJ Frequency of use & Age of onset MJ Use −0.301 0.002
Age
b onset of MJ use & Altered concentration
and memory
0.222* 0.027
a. The first seven correlations are Pearson, 24 analyses ran and the eighth
correlation is PHI, 16 analyses ran.
b. Based on the two categories above and below the mean.
c. Bonferonni Correction not used regarding these correlations.
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and will require replication in larger studies.
The earlier the age of onset of cannabis use, the more
likely one experienced delusions or paranoia. One might
speculate that this effect may have to do with the level
of brain maturation at the time of onset of use and how
much cannabis can then alter the course of that
development.
Twenty-six percent of individuals in this study met
lifetime criteria for social anxiety disorder, a similar as-
sociation having been reported by [13-15]. Perhaps this
personality trait may lead people to use cannabis so that
they can feel more relaxed in social situations, although
we do not have an estimate of the percentage of non-
cannabis using persons who also exhibit social anxiety
and this may simply be a common trait in general.
Barkus and Lewis [16] reported that schizotypy was
associated with psychosis-like effects of cannabis and
proposed that people with schizotypy might be more
vulnerable to developing a psychosis when using canna-
bis. The current study fails to confirm this finding.
Table 5 Factor scores & variables
Variables N Mean T Value P value
Age MJ Use
a Factor Score 3
Absent 43 0.329 2.963 0.004
Present 57 −0.248
Depression Factor Score 2
Absent 81 0.154 4.28 0
Present 19 −0.657
Depression Factor Score 4
Absent 81 0.073 2.362 0.021
Present 19 −0.313
Social Anxiety Factor Score 2
Absent 74 1.02 2.891 0.005
Present 26 0.8
Fam Hx Schizo Factor Score 1
Absent 90 0.039 2.151 0.043
Present 10 −0.351
Fam Hx MD Factor Score 5
Absent 86 0.9 −2.089 0.039
Present 14 1.41
Family Hx Alc Factor Score 2
Absent 68 0.137 2.036 0.046
Present 32 −0.291
Family Hx Alc Factor Score 3
Absent 68 −0.148 −2.204 0.03
Present 32 0.315
a. Based on the two categories above and below the mean, 16 years old.
b. Variables: Hx=History, BP=Bipolar Disorder, Alc=Alcoholism.
Table 6 Significant chi-square analyses for symptoms of
cannabis
Cannabis symptoms CHI P-value
Hallucinations
Alcohol Usage No Yes
Absent 6 87 10.5 0.001
Present 3 4
Alt. Appetite
Social Anxiety No Yes




Absent 39 42 5.877 0.015
Present 15 4
Alt. Appetite
Depression No Yes 0.001
Absent 43 38 11.22
Present 18 1
a. Variables: Hx=History, BP=Bipolar Disorder, Alc=Alcoholism.
Table 7 Family history of major depression (MD),
alcoholism (Alc),schizophrenia (Schiz) or bipolar disorder
(BP) and cannabis symptoms
Family Hx Symptoms CHI P-value
Sad, Lonely etc.
Family Hx MD No Yes
Absent 79 9 8.7 0.003
Present 7 5
Racing thoughts etc.
Family Hx Alc No Yes
Absent 67 26 10 0.002
Present 1 6
Alcohol Usage
Family Hx Alc No Yes
Absent 4 64 2.5 0.112
Present 5 27
Hallucinations
Family Hx Schiz No Yes
Absent 84 6 0.2 0.695
Present 9 1
Sad Lonely etc.
Family Hx BP No Yes
Absent 79 9 8.7 0.003
Present 7 5
a. Variables: Hx=History, BP=Bipolar Disorder, Alc=Alcoholism.
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schizotypal traits did not more frequently report any
evidence of psychosis than those who did not have
these traits.
Limitations of this study include (1) many of the vari-
ables ascertained were provided by self-report by each
subject studied and thus relying on not only retrospect-
ive recall of events, but truthfulness of each individual,
which is an important drawback of this study. Only a
prospective longitudinal study with objective measures
observed by a third party would be more definitive. And
(2), that our numbers for those individuals whose family
members reported major mental illness among relatives
were small and thus our negative findings are not defini-
tive and need to be confirmed in larger studies.
In summary, we were unable to show that having a
family history of a psychotic illness and thus presumably
carrying genes for these illnesses could lead to a ten-
dency to have symptoms characteristic of these illnesses
when using cannabis. This could simply be due to the
small N of those with family history of mental illness, or
could be an initial important finding, given that there is
much controversy about whether cannabis itself can
cause schizophrenia and has long been considered an
environmental risk factor for developing this illness [17].
Larger studies will need to be performed with greater
power to see if this finding is confirmed. Nevertheless, it
i sn o t a b l et h a tt h e r ea r em a n yd i f f e r e n te f f e c t so f
cannabis when used as a recreational drug and only
20% of the participants in this study felt “euphoric
and happy” with its use, while 40% reported feeling
paranoid. These variable effects of the drug and their
frequency should be considered as cannabis now has
become legalized in several states in the USA and
world-wide for a wide variety of medicinal purposes.
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